Which of the following drug–drug combinations should be avoided because of high risk of serious toxicity due to interaction via CYP3A4 inhibition?
Show answer and explanation
Correct answer: Erythromycin + simvastatin
Erythromycin is a known CYP3A4 inhibitor. When combined with simvastatin (metabolized by CYP3A4), it can substantially increase statin levels and risk of rhabdomyolysis or other statin-associated toxicities.
Practice all 19 Adverse Drug Reactions and Interactions questions
Keep practicing
More Adverse Drug Reactions and Interactions questions
- When a patient’s renal function declines markedly, what happens to clearance and risk of drug toxicity for renally excreted drugs?
- Which of the following describes a beneficial drug–drug interaction (rather than a harmful one)?
- In older adults, why is the risk of adverse drug reactions higher than in younger adults?
- Which of the following is true about drug interactions involving food or beverages?
- A patient on two drugs that both depress bone marrow function is at increased risk for severe neutropenia. This is an example of which type…
- What is the first step in evaluating a suspected adverse drug reaction in a patient?